Table 2.

Descriptive data of enrolled patients.

Patient	Age	Sex	Primary Disease	Type of Administered ONJ-Related Drugs	Duration (Months)	Cumulative Dose	Chemo-Therapy	Other Medications	Other Diseases	Smoking Habit	MRONJ Location
#1	52	F	MTS/BC	Bevacizumab	4	4800 mg	No	No	No	No	Maxilla (single–right side)
#2	74	M	MTS/PC	Denosumab	8	60 mg	Yes	Prednisone	Hypertension	No	Mandibula (single–right side)
#3	73	M	MM	Zoledronate	7	5 mg	No	Prednisone	Hypertension and ischemic cardiomyopathy	Yes	Mandibula (single–right side)
#4	49	M	MTS/PC	Denosumab	36	360 mg	Yes	No	No	Yes	Maxilla and mandibula (multiple–right maxilla and left mandibula)
#5	48	M	MTS/LC	Denosumab	12	120 mg	No	Nintedanib	No	Yes	Maxilla and mandibula (multiple–right maxilla and left mandibula)
#6	46	F	MTS/BC	Ibandronate Denosumab Everolimus	1 38 39	3 mg 360 mg 11,700 mg	Yes	No	No	No	Mandibula (single–left side)
#7	83	M	MTS/PC	Zoledronate Denosumab	168 24	70 mg 180 mg	Yes	No	Atherosclerosis	No	Maxilla and mandibula (multiple–left maxilla and mandibula)

Legend: MM = multiple myeloma; MTS/BC = metastasis/breast cancer; MTS/PC = metastasis/prostate cancer; MTS/LC = metastasis from lung cancer;